CT, MRI, PET, and PET/CT

Comparison table of CT, MRI, PET, and PET/CT in oncology tailored for a pharmacist’s perspective:

<

p data-start=”0″ data-end=”120″>

Imaging Modality Principle Primary Oncology Uses Advantages Key Pharmacist Considerations
CT (Computed Tomography) X-rays + computer processing → cross-sectional images Tumor detection, staging, treatment planning, surveillance Fast, widely available, good spatial resolution, detects bone/soft tissue Contrast nephrotoxicity (iodinated contrast), allergy risk, radiation exposure, metformin precautions
MRI (Magnetic Resonance Imaging) Magnetic field + radiofrequency → detailed soft tissue imaging CNS tumors, liver metastases, pelvic tumors, musculoskeletal tumors Superior soft tissue contrast, no ionizing radiation, multiplanar imaging Claustrophobia, metallic implants, gadolinium contrast (risk of nephrogenic systemic fibrosis in severe renal impairment), contrast allergy
PET (Positron Emission Tomography) Radioactive tracer (e.g., 18F-FDG) → detects metabolic activity Staging, recurrence detection, treatment response Detects metabolically active disease, identifies occult metastases Fasting required, hyperglycemia affects accuracy, radiation exposure, tracer availability, patient counseling on prep
PET/CT Combines PET metabolic info + CT anatomical info Comprehensive staging, treatment response, recurrence monitoring Combines metabolic + structural data, more accurate than PET alone Same as PET + CT: contrast, radiation, prep, renal function, patient counseling

Summary:

  • CT: fast, structural imaging; watch contrast and renal function.
  • MRI: excellent soft tissue detail; watch for gadolinium safety.
  • PET: shows metabolic activity; prep and blood sugar matter.
  • PET/CT: combines both, offering highest staging accuracy; same safety considerations.